AmplifyBio to make substantial investment in New Albany business park
AmplifyBio, a biotechnology contract research organization, is investing roughly $150 million in a new 350,000-square-foot facility at 9885 Innovation Campus Way in the New Albany International Business Park.
Along with the investment, the company is also creating 263 new jobs across both its new location and its existing West Jefferson location. Hiring for research and development positions is to be ongoing through 2022.
Company officials announced their plans through a press release May 23.
AmplifyBio is supporting advanced therapies using a variety of modern clinical and commercial drug development solutions, according to the press release.
“The company focuses on safety, efficacy and toxicology testing for best-in-class and advanced therapy drug candidates to accelerate the development of scalable products,” the release said.
“In 2021, AmplifyBio raised $200 million in early-stage venture capital investments – the second largest (venture capital) investment in the Columbus region last year.”
Some details are not clear, such as whether the company is to seek a tax abatement through New Albany City Council.
Scott McAfee, spokesperson for New Albany, said he was aware of the development, but didn’t know when it was going to be announced.
“We are excited to welcome AmplifyBio to our community’s burgeoning health and life sciences cluster, which is already home to industry leaders such as Amgen,” Jennifer Chrysler, New Albany’s director of community development, said in a prepared statement.
“Our community’s international business park offers shovel-ready sites, redundant and reliable utilities and is a stone’s throw from one of the nation’s largest public research universities,” Chysler said, referring to Ohio State University.
“When our clients need to quickly establish and scale operations, they know that they can achieve success in New Albany because we have made all the necessary investments to welcome them while reducing their development costs.”